Clinical Trials Logo

Fabry Disease, Cardiac Variant clinical trials

View clinical trials related to Fabry Disease, Cardiac Variant.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05039866 Enrolling by invitation - Fabry Disease Clinical Trials

Long-Term Follow-up of Subjects Who Were Treated With ST-920

Start date: August 16, 2021
Phase:
Study type: Observational

Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.

NCT ID: NCT04943991 Enrolling by invitation - Fabry Disease Clinical Trials

Fabry Disease in High-risk Patients With Left Ventricular Hypertrophy: Prevalence and Implementation of a Clinical Score

FAPREV-HCM
Start date: July 1, 2021
Phase: N/A
Study type: Interventional

This study aims to evaluate the prevalence of Fabry Disease (FD) among a cohort of high risk patients with left ventricular hypertrophy (LVH) presenting at the University Hospital Würzburg over the last 20 years. Fabry disease is a rare disease that is known to be consistently underdiagnosed due to its largely variable symptoms. Considering that an early Fabry diagnosis is crucial for maximum benefit from therapies available, screening for Fabry patients can contribute to preventing development and worsening of symptoms in Fabry patients with LVH. In addition, a positive diagnosis in a family member opens the possibility to diagnose further family members in an earlier stage of the disease, therefore allowing treatment of symptoms and organ manifestations before they become irreversible.